Ventis Pharma Announces U.S. Commercial Launch of a new Sufentanil/Ketamine Nasal Spray, a 503B Medication...
Ventis Pharma Announces Commercial Launch of SafeTuck™, a Surgeon-Developed Surgical Patient Positioning...
A Three-arm Randomized Clinical Trial Comparing Continuous Femoral Plus Single-injection Sciatic Peripheral...
EXTENDED DURATION LOCAL ANESTHETIC FORMULATION
An extended duration anesthetic includes a short duration
local...
Ventis Pharma’s Success at ASRA and COA Conferences: A Glimpse into a Bright Future
We are thrilled...